Adverse Events of All Severities and Treatment Relationship With a Difference of ≥5% in Incidence Between the Treatment Groups
| . | Filgrastim (n = 103) . | SCF + Filgrastim (n = 100) . | P Value4-150 . |
|---|---|---|---|
| Injection site reactions | 10% | 92% | <.0001 |
| Dizziness | 6% | 12% | .142 |
| Tachycardia | 0% | 8% | NA |
| Dyspnea | 2% | 8% | .055 |
| Hypocalcemia | 3% | 8% | .129 |
| Pruritus | 1% | 6% | .061 |
| Paresthesia | 35% | 29% | .453 |
| Nausea | 23% | 16% | .221 |
| Headache | 23% | 13% | .071 |
| . | Filgrastim (n = 103) . | SCF + Filgrastim (n = 100) . | P Value4-150 . |
|---|---|---|---|
| Injection site reactions | 10% | 92% | <.0001 |
| Dizziness | 6% | 12% | .142 |
| Tachycardia | 0% | 8% | NA |
| Dyspnea | 2% | 8% | .055 |
| Hypocalcemia | 3% | 8% | .129 |
| Pruritus | 1% | 6% | .061 |
| Paresthesia | 35% | 29% | .453 |
| Nausea | 23% | 16% | .221 |
| Headache | 23% | 13% | .071 |
Abbreviation: NA, P value could not be computed.
P value from Fisher Exact test.